Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionMackenzie Financial Corp
Latest Disclosed Ownership22,507 shares
Latest Disclosed Value $ 7,446,891
Mackenzie Financial Corp reports 81.58% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 22,507 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $6,430,250 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 12,395 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 81.58% during the quarter. The current value of the position is $5,667,263 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,507 10,112 81.58 7,447 51.53 0.0089
2026-02-18 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,395 2,622 26.83 4,914 10.28 0.0058
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,773 698 7.69 4,456 50.59 0.0054
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,075 -410 -4.32 2,959 15.54 0.0038
2025-05-07 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,485 626 7.07 2,561 22.89 0.0036
2025-05-02 2024-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,859 -10,832 -55.01 2,085 -61.51 0.0028
2025-02-20 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,859 -10,832 2,085 0.0027
2025-02-14 2024-12-31 13F Alnylam Pharmaceuticals Common Stock 02043Q107 8,859 -10,832 1,213 0.0017
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,691 -16,400 -45.44 5,416 -38.26 0.0075
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,091 17,576 94.93 8,770 216.95 0.0130
2024-05-10 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,515 -1,821 -8.95 2,767 -28.91 0.0040
2024-01-30 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,336 -1,410 -6.48 3,893 3.51 0.0059
2023-10-25 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,746 -8,350 -27.74 3,760 -34.13 0.0063
2023-08-03 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,096 4,299 16.66 5,709 10.47 0.0087
2023-04-24 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,797 580 2.30 5,168 -13.77 0.0080
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,217 1,703 7.24 5,993 27.30 0.0100
2022-10-07 2022-09-30 13F Alnylam Pharmaceuticals Common Stock 02043Q107 23,514 2,508 11.94 4,707 53.62 0.0081
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,006 1,630 8.41 3,064 -3.16 0.0049
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,376 1,965 11.29 3,164 7.15 0.0042
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,411 1,756 11.22 2,953 -0.10 0.0040
2021-11-08 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,655 2,915 22.88 2,956 36.85 0.0042
2021-08-11 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,740 1,651 14.89 2,160 37.93 0.0030
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,089 1,601 16.87 1,566 27.01 0.0024
2021-02-10 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,488 -419 -4.23 1,233 -14.49 0.0027
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,907 -7,131 -41.85 1,442 -42.85 0.0036
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,038 13,394 367.56 2,523 535.52 0.0068
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,644 865 31.13 397 24.06 0.0013
2020-02-13 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,779 2,779 320 0.0008
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,075 -100.00 0 -100.00
2019-08-23 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 5,075 -6,918 -57.68 368 -67.17 0.0009
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,075 -6,918 368
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,993 5,794 93.47 1,121 148.01 0.0027
2019-02-06 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,199 -32,096 -83.81 452 -86.52 0.0012
2018-11-15 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,295 33,911 773.52 3,352 675.93 0.0082
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,384 -12,881 -74.61 432 -78.99 0.0011
2018-05-14 2018-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 17,265 17,265 2,056 0.0052
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,265 2,056 0.0052
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.